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ABSTRACT
For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell
transplants for adult recipients. In this time period, the volunteer donor pool has expanded to nearly 12 million
adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching,
there have been many changes in clinical practice and supportive care, and the more common graft source has
shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs). The percentage of older patients
who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients
is over the age of 60 years. Chronic myelogenous leukemia (CML) was previously the most common diagnosis
for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients.
Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lym-
phoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related mortality
(TRM) has declined significantly over the years, particularly in association withmyeloablative transplant prepar-
ative regimens. Correspondingly, survival within each disease category has improved. Particularly gratifying are
the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years.
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Since its establishment in 1987,.30,000 unrelated
donor hematopoietic cell transplants (HCT) have been
facilitated by the National Marrow Donor Program
(NMDP). HCT recipients in .70% of cases were
adults with hematologic malignancies or acquired
hematologic conditions. The history of the NMDP
has been recently reviewed [1]. Much has changed in
20 years, including a vastly increased volunteer adult
donor pool, introduction of peripheral blood stem8cells (PBSCs), addition of umbilical cord blood
(UCB) units, and dramatic advances in HLA-typing
andmatching technology. Additional advances include
the introduction of new pharmaceutical agents, refine-
ment of conditioning regimens through strategies such
as targeted dosing and reduced-intensity conditioning
(RIC), and the application of post-transplant immuno-
modulation. This review will examine the experiences
of adult recipients of HCT facilitated by the NMDP
over the past 20 years.
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1987-1995 1996-1998 1999-2002 2003-2006
N % N % N % N %
Number of recipients 2052 1930 3224 4212
Follow-up time among survivors in Days
Median (range) 4536 (273-7034) 3296 (371-4293) 2154 (120-3247) 757 (63-1739)
Diagnosis
Acute myelogenous leukemia (AML) 422 21 469 24 967 30 1639 39
Acute lymphoblastic leukemia (ALL) 227 11 241 12 502 16 528 13
Chronic myelogeneous leukemia (CML) 1065 52 802 42 683 21 405 10
Myelodysplastic disorders (MDS) 176 9 213 11 439 14 594 14
Non-Hodgkin lymphoma (NHL) 53 3 112 6 401 12 609 14
Hodgkin lymphoma (HD) 7 \1 12 1 87 3 204 5
Multiple myeloma (MM) 24 1 41 2 83 3 119 3
Severe aplastic anemia 78 4 40 2 62 2 114 3
Disease Risk AML, ALL, CML, MDS
Early 841 44 762 44 956 37 1124 36
Intermediate 674 36 565 33 889 34 1115 35
Advanced 331 18 338 20 572 22 669 21
Unknown status or unclassified 44 2 60 3 174 7 258 8
Time from diagnosis to transplant in months
Median (range) 16.2 (0-325) 13.3 (0-309) 12.5 (0-316) 12.9 (0-316)
\6 182 9 288 15 615 19 988 23
6-12 550 27 591 31 939 29 1026 24
12-24 619 30 533 28 760 24 888 21
$24 689 34 508 26 886 27 1289 31
Unknown 12 1 10 1 24 1 21 \1
Recipient age in years
Median (range) 35.6 (18.0-58.8) 38.6 (18.0-65.9) 41.5 (18.0-79.3) 46.7 (18.0-78.1)
18-35 1061 52 801 42 1166 36 1216 29
36-60 991 48 1122 58 1928 60 2524 60
61-70 0 0 7 \1 126 4 453 11
$71 0 0 0 0 4 \1 19 \1
Graft type
Bone marrow 2052 100 1930 100 2237 69 1180 28
PBSC 0 0 0 0 969 30 2913 69
Cord blood unit 0 0 0 0 18 1 119 3
HLA match
Well matched 575 28 545 28 1659 51 2745 65
Partially matched 642 31 889 46 1048 33 1085 26
Mismatched 835 41 496 26 517 16 367 9
Unknown 0 0 0 0 0 0 15 \1
Conditioning regimen
Myeloablative 1772 86 1822 94 2366 73 2294 54
Reduced intensity/nonmyeloablative 59 3 105 5 856 27 1911 45
Unknown 221 11 3 \1 2 \1 7 \1
First transplant NHL, HD, myeloma
Yes 68 81 123 75 300 53 407 44
No; prior autologous 16 19 42 25 271 47 525 56
HD indicates Hodgkin lymphoma.Data Collection
The study population included 11,418 adult pa-
tients 18 years or older who received unrelated donor
(URD) transplants through the NMDP from Decem-
ber 1987 throughMarch 2006 for acute myelogeneous
leukemia (AML), acute lymphoblastic leukemia
(ALL), chronic myelogeneous leukemia (CML), mye-
lodysplastic disorders (MDS), non-Hodgkin lym-
phoma (NHL), Hodgkin disease (HD), multiple
myeloma (MM), and severe aplastic anemia (SAA).
Only AML, ALL, CML, MDS, and SAA recipientswith a primary unrelated donor transplant and NHL,
HD, and MM recipients with a primary URD trans-
plant or a URD second transplant with a prior autolo-
gous transplant were included in the study population.
Data from this cohort were collected on standard
NMDP forms and included predominately U.S. recip-
ients, and only those from whom informed consent
was documented. A total of 1488 recipients were omit-
ted from the study because of consent issues.
These data were grouped into 4 time periods
(1987-1995, 1996-1998, 1999-2002, and 2003-2006)
10 C. Karanes et al.of similar length and approximately similar numbers of
patients. A longer early period (1987-1995) was chosen
to have enough cases for analysis.
Statistical Analysis and Definitions
Probabilities of survival were calculated using the
Kaplan-Meier method. Survival curves were truncated
at 2 years because of short follow-up in the most recent
time period. With second transplants for NHL, the
first 2 time periods were collapsed because of small
sample sizes. Neutrophil engraftment was defined as
an achievement of an absolute neutrophil count of
$500 neutrophils/mm3 sustained for 3 consecutive
laboratory measurements on different days. Platelet
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Figure 1. Number of adult transplants in the study population for
each disease by transplant period. Transplant numbers for all dis-
eases except CML have increased over the 4 time periods.engraftmentwas defined as an achievement of a platelet
count recovery of$50,000 platelets/mm3 sustained for
3 consecutive laboratory measurements on different
days with no platelet transfusions in the previous
7 days. Probabilities of neutrophil and platelet engraft-
ment were calculated using the cumulative incidence
method, with death without engraftment as a com-
peting risk. Treatment-related mortality (TRM)
was defined as death without relapse, and was calcu-
lated using the cumulative incidence method, with
relapse treated as a competing risk. Engraftment and
TRM were censored at occurrence of a second trans-
plant. Chi-square tests were used for pointwise rate
comparisons.
Disease risk was defined as early (first complete
remission for acute leukemia, first chronic phase for
CML, and MDS-refractory anemia or acquired idio-
pathic sideroblastic anemia), intermediate (first relapse
or second or greater complete remission for acute leu-
kemia, and second chronic phase or accelerated phase
for CML), or advanced (second or greater relapse for
acute leukemia, CML-blast phase, and MDS-refrac-
tory anemia with excess blasts, or refractory anemia
with excess blasts in transformation). Disease risk
was not classified for NHL, HD, myeloma, or SAA.
Myeloablative conditioning regimens included 1 of
the following: total body irradiation (TBI) dose
.500 cGy as a single fraction, TBI dose.800 cGy re-
gardless of the number of fractions, melphalan (Mel)
dose .150 mg/m2, busulfan (Bu) dose $9.5 mg/kg,
any combination of Mel and Bu, or any combination
of Cyclophosphamide (Cy), Etoposide (VP-16), and
TBI. All other regimens were considered non-myeloa-
blative/reduced intensity conditioning (RIC). BasedTable 2. Treatment-Related Mortality for Adult Recipients with Leukemia and Myelodysplastic Syndromes
1988-1995 1996-1998 1999-2002 2003-2006
N
Prob
(%)
95%
CI N
Prob
(%)
95%
CI N
Prob
(%)
95%
CI N
Prob
(%)
95%
CI
Pointwise
P-value
Myeloablative bone marrow 1647 1666 1648 711
at 100 days post-HCT 35 33-38 36 33-38 28 26-30 16 14-19 \.0001
at 1 year post-HCT 53 50-55 51 49-53 41 39-44 28 25-31 \.0001
at 2 years post-HCT 56 54-59 54 52-57 45 43-48 32 29-36 \.0001
Myeloablative PBSC 0 0 448 1270
at 100 days post-HCT — — 25 21-29 18 16-20 .005
at 1 year post-HCT — — 42 37-47 31 28-33 \.0001
at 2 years post-HCT — — 45 41-50 35 32-38 .0002
Non-myeloablative bone
marrow
17 44 188 198
at 100 days post-HCT 35 15-59 42 27-57 20 15-27 17 12-23 .01
at 1 year post-HCT 41 19-65 49 34-64 35 28-42 32 25-38 .20
at 2 years post-HCT 41 19-65 49 34-64 38 31-45 37 30-44 .52
Non-myeloablative PBSC 0 271 876
at 100 days post-HCT — 19 15-24 13 11-15 .01
at 1 year post-HCT — 37 31-42 26 23-29 .002
at 2 years post-HCT — 41 35-47 30 27-33 .001
CI indicates confidence interval; MDS, myelodysplastic syndromes.
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1988-1995 1996-1998 1999-2002 2003-2006
N
Prob
(%)
95%
CI N
Prob
(%)
95%
CI N
Prob
(%)
95%
CI N
Prob
(%)
95%
CI
Pointwise
P-value
Bone marrow 35 26 34 54
at 100 days post-HCT 47 30-64 59 40-77 24 11-39 15 7-26 \.0001
at 1 year post-HCT 62 45-78 68 49-85 43 27-60 25 14-38 .0001
at 2 years post-HCT 66 49-81 73 54-88 43 27-60 33 20-47 .0009
PBSC 0 0 8 30
at 100 days post-HCT — — 38 9-71 20 8-35 .33
at 1 year post-HCT — — 63 29-91 26 12-43 .06
at 2 years post-HCT — — 63 29-91 32 16-51 .12
CI indicates confidence interval.on the best available typing data at the time of analysis,
HLA matching was classified into 3 categories (well-
matched, partially matched, and mismatched) accord-
ing to a recently developed algorithm that considers
level of HLA-typing resolution and matching at
HLA-A, -B, -C, and -DRB1 loci [2]. Well-matched
cases had either no identified HLA mismatch and in-
formative data at 4 loci or allele matching at HLA-A,
-B, and -DRB1. Partially matched pairs had a defined,
single locus mismatch and/or missing HLA data. Mis-
matched cases had $2 allele or antigen mismatches.
RESULTS
Numbers and characteristics of adult HCT pa-
tients in the study population during each of the
4 time periods are shown in Table 1. Fifty-six percent
of patients with AML, ALL, CML, or MDS were
transplanted with intermediate or advanced disease
during the most recent period, compared to 53%from 1987 through 1998. Over time, the use of HCT
in older age patients has increased. The median age
of adult patients has increased by 11 years to 46.7 years,
with 11% of patients in the most recent period (2003-
2006) aged.60 years. Patients receiving well-matched
donors accounted for 65% for all HCTs during
2003-2006, compared to 28% of patients transplanted
during 1987-1995 and 1996-1998.
Indications for Transplants
The distribution of diseases for which unrelated
donor HCT was preformed has changed dramatically
over time (Figure 1). In the most recent time period,
patients in the study population with AML accounted
for 39% of unrelated donor HCTs followed by NHL
(14%), MDS (14%), and ALL (13%) (Table 1). CML
was previously the single most common indication for
unrelated donor HCT (52% of all transplants from
1987 through 1995), but only accounted for 10% of
HCTs in the most recent time period. Among 4212Figure 2. (A) Survival of adults with AML after HCT during 4 time periods. Survival is significantly better at 2 years post-transplant for patients
transplanted during 2003-2006 compared to 1999-2002 (P# .008) and also compared to 1996-1998 and 1987-1995 (P\ .0001). (B) Survival of
adults with AML after HLA well-matched HCT during 4 time periods. Survival is significantly better (P\ .0001) at 2 years post-transplant for
patients transplanted during 1999-2002 and 2003-2006 compared to patients transplanted during 1987-1998 and 1996-1998.
12 C. Karanes et al.adults transplanted from unrelated donors from 2003
to 2006, only 5% hadHD, 3%myeloma, and 3% SAA.
HLA Matching
There has been an increasing percentage of HLA
well-matched donor-recipient pairs over time (Table
1). In the 2 early time periods, only 28% of the
donor-recipient pairs met the definition of well-
matched in contrast to 51% and 65% in 1999-2002
and 2003-2006, respectively. Frequency of HLA-
mismatching category has similarly declined over
time (41%, 26%, 16%, and 9%, respectively).
Stem Cell Sources
Bone marrow was the only graft source available
for primary unrelated donor HCT through the
NMDP until July of 1999. Since the introduction of
Figure 3. Survival of adults with ALL after HCT during 4 time
periods. Survival is significantly better (P\ .0001) at 2 years post-
transplant for patients transplanted during 2003-2006 compared to
patients transplanted during the previous periods.
Figure 4. Survival of adults with MDS after HCT during 4 time
periods. Survival is significantly better (P\ .0001) at 2 years post-
transplant for patients transplanted during 2003-2006 compared to
patients transplanted during the previous periods.a protocol for collection of PBSC, there has been a
steady increase in the use of this graft source. In the
study population during the period from 2003 to
2006, PBSC accounted for 69% of all unrelated donor
HCT. There were 137 adult patients who received
UCB unit transplantation through the NMDP in this
analysis.
Engraftment
Only patients receiving myeloablative preparative
regimens were analyzed for neutrophil and platelet
engraftment. The cumulative incidence of neutrophil
engraftment was 95% for patients in the 2003-2006
period compared to 90% for the period from 1987-
1995 (P \ .0001). The median time to neutrophil
engraftment among patients who engrafted was 19
days in 1987-1995, 18 days in 1996-1998, 17 days in
1999-2002, and 15 days in 2003-2006. Platelet en-
graftment to 50,000 occurred in 70% of patients
transplanted in 2003-2006 compared to only 27% in
1987-1995. The median time to platelet engraftment
among patients who engrafted was 33 days in 1987-
1995, 32 days in 1996-1998, 28 days in 1999-2002,
and 23 days in 2003-2006.
TRM
For leukemia and MDS patients receiving bone
marrow following myeloablative regimens, the TRM
at 100 days, 1 year, and 2 years decreased significantly
over the time intervals studied. One hundred-day
TRM was 35%-36% in the periods 1988-1995 and
1996-1998 and decreased to 28% in 1999-2002 and
16% in 2003-2006 (P \ .0001) (Table 2). Similar
decreases in TRM were observed at 1 year and 2 years
posttransplant. One hundred-day TRM for patients
receiving PBSC grafts with myeloablative condition-
ing declined from 25% to 18% in the intervals 1999-
2002 and 2003-2006, respectively (P 5 .005). Among
these patients there was also decreasing TRM at
1 and 2 years (Table 2).
For patients with NHL and HD who received
myeloablative unrelated donor transplants as a first
transplant, there was significant improvement in
TRM from the earlier time period (1990-2002) to
the most recent period (2003-2006) (100-day: 35%
versus 21% [P 5 .002], 1-year: 48% versus 32% [P
5 .001], and 2-year: 51% versus 37% [P 5 .005]).
However, for NHL and HD patients who were trans-
planted between 2003 and 2006 and received non-
myeloablative regimens, TRM was lower still at
10%, 20%, and 25% at 100 days, 1 year, and 2 years,
respectively.
TRM for patients with NHL and HD who had
prior autologous transplants was high in all time pe-
riods. With myeloablative regimens, 1-year TRM
was 70% prior to 1999, 44% between 1999 and
NMDP Adult Hematopoietic Cell Transplantation 13Figure 5. (A) Survival of adults with CML after HCT during 4 time periods. Survival is significantly better at 2 years post-transplant for patients
transplanted during 2003-2006 compared to patients transplanted during 1987-1995 and 1996-1998 (P\ .0001), but was not significantly dif-
ferent compared to patients transplanted during 1999-2002. (B) Survival of adults with CML inCP1, CP2/accelerated, or blast phase after HCT.
Survival is significantly better (P\ .0001) at 2 years post-transplant for patients transplanted during CP1 compared to the other phases. Survival
is also significantly better (P\ .0001) at 2 years post-transplant for patients transplanted during CP2/accelerated phase compared to blast phase.2002, and 43% for the interval 2003-2006 (P 5 .05).
Patients with prior autologous transplants who
received non-myeloablative regimens exhibited lower
TRM (25% at 1 year), which has not changed over
time.
There has been a major reduction of TRM for
SAA patients who received bone marrow transplants
following non-myeloablative preparative regimens
(Table 3). In the most recent time period (2003-
2006) TRM at 100 days, 1 year, and 2 years was
15%, 25%, and 33%, respectively. Among 30 SAA
patients who received PBSC after nonmyeloablative
regimens during 2003-2006, the TRM was 20% at
100 days, 26% at 1 year, and 32% at 2 years.
Figure 6. Survival of adults with SAA after HCT during 4 time
periods. Survival is significantly better at 2 years post-transplant for
patients transplanted during 2003-2006 compared to patients trans-
planted during 1987-1995 and 1996-1998 (P\ .0001), but was not
significantly different compared to patients transplanted during
1999-2002.Survival Over Time for Specific Diseases
The 2-year survival rate for AML patients has in-
creased over time (Figure 2A). In the earlier time pe-
riods (1987-1995 and 1996-1998) survival was 21%
and 20%, respectively, increasing to 31% in 1999-
2002 and 37% in 2003-2006 (P\ .0001). Even among
patients whose donors were HLA well-matched, sur-
vival has improved over time (Figure 2B).
For ALL, the 2-year survival rate in the most
recent time period was 41%, compared with values
in each previous time period of 28%, 22%, and 23%,
respectively (Figure 3; P\ .0001). Again, similar to
the observation in AML, among ALL patients with
HLA well-matched donors, survival has improved
over time (data not shown).
The 2-year overall survival (OS) rate for patients
with MDS has improved from 27%, 31%, and 32%,
respectively, in the 3 early time intervals to 43% in
2003-2006 (Figure 4; P \ .0001). However, when
HLA match was analyzed, there has been no signifi-
cant improvement of survival over time for recipients
of well-matched or partially-matched grafts (data not
shown). The MDS recipients of mismatched grafts
from the most recent period had significantly better
OS of 37% compared to 9%-19% survival when trans-
planted in the earlier 3 periods (P 5 .005).
The 2-year survival rate for CML patients was
54% in 2003-2006 compared to 37% in 1987-1995
and 42% in 1996-1998 (Figure 5A; P \ .0001). As
shown in Figure 5B, and as expected, CML patients
transplanted in first chronic phase did better than
those with more advanced disease.
The 2-year survival rate of patients transplanted
for SAA has doubled in the past 10 years (Figure 6).
Survival rates of 31% and 27%, respectively, were
14 C. Karanes et al.Table 4. Overall Survival for Non-Hodgkin Lymphoma Patients—First URD Transplant and URD Transplant following a Prior Autologous Transplant
1988-1995 1996-1998 1999-2002 2003-2006
N Prob (%) 95% CI N Prob (%) 95% CI N Prob (%) 95% CI N Prob (%) 95% CI Pointwise P-value
First HCT 51 89 263 366
at 1 year post-HCT 37 25-51 36 26-46 39 33-45 54 49-59 .0002
at 2 years post-HCT 29 18-43 31 22-41 33 28-39 43 38-48 .02
HCTwith
prior autologous
0 23 136 241
at 1 year post-HCT — 17 5-35 40 32-48 46 39-52 .004
at 2 years post-HCT — 12 2-29 33 25-41 37 31-43 .005
CI indicates confidence interval; URD, unrelated donor.observed in the time periods 1987-1995 and 1996-
1998. Survival in 1999-2002 jumped to 53% and
climbed further to 62% in the most recent interval (P
\ .0001). SAA patients with HLA well-matched grafts
had a 2-year survival rate of 78% in the most recent
interval, 2003-2006.
Survival of NHL patients was analyzed in 2 sepa-
rate categories: those who received unrelated donor
HCT as first transplants and those who had prior au-
tologous HCT. There has been significant improve-
ment of 2-year OS over time for both groups (Table
4). In the earliest time period of 1996-1998, the 1-
year and 2-year survival was 17% and 12% for patients
with a prior autologous transplant compared to 1-year
survival of 46% and 2-year survival of 37% in the most
recent period of 2003-2006 (P 5 .004 at 1 year; P 5
.005 at 2 years). For patients who received URD
HCT as a first transplant, the 1- and 2-year survival
in the most recent period of 54% and 43% was better
than 1- and 2-year survival of 37% and 29%, respec-
tively, in the earlier time periods (P 5 .0002 at
1 year, P 5 .02 at 2 years).
There were only 80 patients with multiple mye-
loma (MM) who underwent unrelated donor HCT as
a first transplant. Among 43 patients transplanted dur-
ing 1987-1998, the 1-year survival was 42%, which was
better than the 22% survival of 37 patients who were
transplanted in the more recent interval from 1999-
2006. One hundred eighty-seven myeloma patients
with prior autologous transplant who subsequently
underwent unrelated donorHCT had 48% 1-year sur-
vival in the period 1999-2006 compared to 20% for
those transplanted from 1987-1998.
DISCUSSION
These data show how practices have changed over
time in the performance of URD HCT for adults. Se-
venty percent of adults currently receive PBSC grafts.
Non-myeloablative regimens have become common
and made up 45% of the transplants performed from
2003-2006. Older patients comprise an increasing per-
centage of the recipient population. AML is now themost common indication for URD transplantation.
There has been dramatic growth in the numbers of
transplants for patients with MDS, NHL, and HD.
CML, which was previously the most common diag-
nosis for HCT, has decreased significantly since the
introduction of imatinib and other tyrosine kinase in-
hibitors. Several factors contributed to these changes
over the past 20 years. The number of volunteer do-
nors has grown to nearly 12 million current registrants
worldwide, making well-matched donors available to
many more patients. More than 250,000 UCB units
are also available.With this growth in available donors
and UCB units, HLA diversity has also increased, en-
abling more patients from diverse ethnic backgrounds
to access HCT therapies. Advances in the HLA typing
and matching technology have facilitated more rapid
identification of better-HLA-matched donors. Analy-
ses of URD bone marrow transplants have shown the
benefit of allele-level matching at HLA-A, -B, -C,
and -DRB1, and potentially additional loci [3-10].
Several articles have also addressed best practices for
optimal donor selection [11-14].
There has been dramatic growth in the use of
PBSC as the graft source for URDHCT. This growth
was driven by transplant physicians who specify their
preferred graft source once a suitable donor is identi-
fied. There should be cautionwith this practice as a ret-
rospective analysis of NMDP data comparing URD
HCT outcome in adults receiving PBSC and bone
marrow found the rates of grade II-IV acute and
chronic graft-versus-host disease (GVHD) were sig-
nificantly higher in recipients of PBSC grafts [15].
There were no differences seen in TRM, leukemia re-
currence, leukemia-free survival (LFS), or OS. A large
randomized prospective comparison of URD bone
marrow and PBSC grafts is underway, sponsored by
the Blood and Marrow Transplant Clinical Trials
Network, which should clarify the risks and benefits
of each graft source.
Striking findings from our analysis are the
decreases over time in TRM for patients in all disease
categories receiving myeloablative preparative regi-
mens. Reductions in TRM have occurred despite
NMDP Adult Hematopoietic Cell Transplantation 15increasing median patient age and similar percentages
of patients with intermediate and advanced disease
risk. Improvements in HLA matching, better support-
ive care particularly in infection management, and bet-
ter GVHD prophylaxis and treatment have probably
played roles in the reduction of TRM [16]. TRM is
low and unchanging for most transplants performed
with non-myeloablative preparative regimens, except
in the case of SAA for which dramatic improvements
in survival and TRM have been demonstrated, partic-
ularly over the past 10 years.
Survival curves for recipients of unrelated donor
grafts show clear improvements over time, with
changes most evident in the recent time period from
2003 through 2006. The survival curves are unad-
justed, and could reflect differences in the patient pop-
ulations within each diagnosis. However, in recent
years many older patients have been transplanted,
more than half the patients have continued to present
with intermediate or advanced disease risk at trans-
plant, and increasingly patients come to URD trans-
plant following a prior autologous transplant.
Although better HLAmatching over time clearly plays
a positive role in increasing survival, improvements in
survival even among the patients with well-matched
donors have been demonstrated.
ACKNOWLEDGEMENTS
Financial Disclosure: Drs. Nelson, Chitphakdithai,
King, and Confer are employees of the NMDP and
have a financial relationship with the NMDP, in that
capacity as employees. Drs. Karanes, Agura, Ballen,
Bolan, Porter, and Uberti have nothing to disclose.
REFERENCES
1. McCullough J, Perkins HA, Hansen J. The National Marrow
Donor Program with emphasis on the early years. Transfusion.
2006;46:1248-1255.
2. Weisdorf D, Spellman S, Haagenson M, et al. Classification of
HLA-matching for retrospective analysis of unrelated donor
transplantation: revised definitions to predict survival. Biol Blood
Marrow Transplant. In press.
3. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of
HLA class I and class II high-resolution matching on outcomes
of unrelated donor bone marrow transplantation: HLA-C mis-matching is associated with a strong adverse effect on transplan-
tation outcome. Blood. 2004;104:1923-1930.
4. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele
mismatch combinations responsible for severe acute graft-
versus-host disease and implication for its molecular mecha-
nism. Blood. 2007;110:2235-2241.
5. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-
recipient HLA matching contributes to the success of unrelated
donor marrow transplantation. Blood. 2007;110:4576-4583.
6. Morishima Y, Sasazuki T, Inoko H, et al. The clinical signifi-
cance of human leukocyte antigen (HLA) allele compatibility
in patients receiving a marrow transplant from serologically
HLA-A, HLA-B, and HLA-DR matched unrelated donors.
Blood. 2002;99:4200-4206.
7. Petersdorf EW, Anasetti C,Martin PJ, et al. Limits of HLAmis-
matching in unrelated hematopoietic cell transplantation. Blood.
2004;104:2976-2980.
8. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histo-
compatibility-complex class I alleles and antigens in hemato-
poietic-cell transplantation. N Engl J Med. 2001;345:
1794-1800.
9. Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA
class II gene disparity on clinical outcome in unrelated donor he-
matopoietic cell transplantation for chronic myeloid leukemia:
the US National Marrow Donor Program Experience. Blood.
2001;98:2922-2929.
10. Shaw BE, Gooley T, Madrigal JA, Malkki M, Marsh SGE,
Petersdorf EW. Clinical importance of HLA-DPB1 in haema-
topoietic cell transplantation. Tissue Antigens. 2007;69(Suppl. 1):
36-41.
11. Confer DL, Miller JP. Optimal donor selection: beyond HLA.
Biol Blood Marrow Transplant. 2007;13:83-86.
12. Hurley CK, Wagner JE, Setterholm MI, Confer DL. Ad-
vances in HLA: practical implications for selecting adult
donors and cord blood units. Biol Blood Marrow Transplant.
2006;12:28-33.
13. KollmanC,HoweCWS, Anasetti C, et al. Donor characteristics
as risk factors in recipients after transplantation of bone marrow
from unrelated donors: the effect of donor age. Blood. 2001;98:
2043-2051.
14. Lee SJ, KamaniN, Confer DL. Principles and tools for selection
of umbilical cord blood and unrelated adult donor grafts. Biol
Blood Marrow Transplant. 2008;14:112-119.
15. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts
from unrelated donors are associated with increased acute and
chronic graft-versus-host disease without improved survival.
Biol Blood Marrow Transplant. 2007;13:1461-1468.
16. Bacigalupo A, SormaniMP, Lamparelli T, et al. Reducing trans-
plant-related mortality after allogeneic hematopoietic stem cell
transplantation. Haematologica. 2004;89:1238-1247.
